Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Cancer immunotherapies have shown great promise, but many tumors can develop resistance as the changing tumor microenvironment can help cancers evade detection and allow cancer cells to proliferate. Teon Therapeutics is developing immno-oncology therapies for difficult to treat cancers that are designed to have the dual effect of restoring immune activity while suppressing cancer cell proliferation. We spoke to Serge Messerlian, CEO of Teon Therapeutics, about what happens when immunotherapies fail, the unique approach Teon is taking, and how the dual activity of its cancer therapies can restore immune activity while suppressing cancer cell proliferation.